Patients with hepatocellular carcinoma: Your address matters!

J Hepatol

Hepatology, Department of Clinical Research, University of Bern, Bern, Switzerland; University Clinic for Visceral Surgery and Medicine, Inselspital Bern, Bern, Switzerland. Electronic address:

Published: March 2017

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2016.11.026DOI Listing

Publication Analysis

Top Keywords

patients hepatocellular
4
hepatocellular carcinoma
4
carcinoma address
4
address matters!
4
patients
1
carcinoma
1
address
1
matters!
1

Similar Publications

Background: Locoregional therapy (LRT) in patients with hepatocellular carcinoma (HCC) before liver transplantation (LT) has a role in improving the tumor biology and post-LT survival outcome apart from downstaging and bridging. We retrospectively analyzed our database of adult living donor liver transplants (LDLT) for HCC, to compare the survival outcomes in Group-1 (upfront-LT, HCC within Milan/UCSF/AFP<1000 ng/ml) and Group-2 (LT post-LRT, HCC beyond UCSF/irrespective of tumor burden with AFP>1000 ng/ml). We also explored the risk factors for recurrence on follow-up.

View Article and Find Full Text PDF

Background: The combination of local therapy with lenvatinib and programmed cell death protein-1 (PD-1) inhibitors represents an emerging treatment paradigm for unresectable hepatocellular carcinoma (uHCC). Our study sought to investigate the interrelationship between gut microbiota and intratumoral microbiota in the context of triple therapy, with a view to identifying potential biological markers.

Methods: The gut microbial community profiles of patients with primary untreated hepatocellular carcinoma (HCC) and those treated with local therapy combined with lenvatinib and PD-1 inhibitors were analyzed by 16S rRNA gene amplicon sequencing.

View Article and Find Full Text PDF

Purpose: The α-FAtE score, composed of alpha-fetoprotein, alkaline phosphatase, and eosinophil levels, has been reported as a predictor of prognosis in hepatocellular carcinoma (HCC) patients treated with atezolizumab plus bevacizumab. This study aimed to investigate the predictive ability of α-FAtE score for the efficacy and safety of locoregional immunotherapy as the treatment of HCC patients.

Methods And Patients: We conducted a retrospective study of 446 HCC patients at Sun Yat-sen University Cancer Center from January 1 2019 to January 1 2023.

View Article and Find Full Text PDF

Background: Infiltrative hepatocellular carcinoma (HCC) remains a therapeutic challenge due to its aggressive course and poor prognosis. Hepatic arterial infusion chemotherapy (HAIC) plus immune checkpoint inhibitors (ICIs) and molecular targeted therapies (MTTs) has shown early promise for advanced HCC, but its role in advanced infiltrative HCC is unclear. This study aims to investigate the efficacy and safety of HAIC combined with ICIs and MTTs in the treatment of advanced infiltrative HCC.

View Article and Find Full Text PDF

Objective: To analyze the efficacy of indocyanine green fluorescence (ICG-F)-assisted laparoscopic hepatectomy in patients with hepatocellular carcinoma (HCC).

Methods: This retrospective study included 120 patients with HCC who underwent laparoscopic hepatectomy in The First Affiliated Hospital of Soochow University from February 2020 to November 2022. Among them, 58 patients underwent conventional laparoscopic surgery (laparoscopic group), and 62 patients underwent ICG-F assisted laparoscopic surgery (ICG-F group).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!